Intelligence · Clinical Development
Pipeline search results
Programs matching “acute-myeloid-leukemia” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 134 pipeline programs matching "acute-myeloid-leukemia" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
TmBU conditioning Regimen
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
VACl
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia, Adult
1 trial -
Venetoclax
Syndax Pharmaceuticals
Acute Myeloid Leukemia
1 trial -
Venetoclax, Azacitidine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Myeloid Leukemia
1 trial -
Venetoclax；Azacitidine；Homoharringtonine
The First People's Hospital of Lianyungang
Secondary Acute Myeloid Leukemia
1 trial -
XMDYYYXYK-04
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
ZN-d5 ZN-c3
Zentalis Pharmaceuticals
Acute Myeloid Leukemia (AML)
1 trial -
anti-CD7 CAR-pNK cells
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
anti-FLT3 CAR-T
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
cytarabine
Teva Pharma GmbH
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
1 trial -
the standard "3+7" regimen
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Newly Diagnosed Acute Myeloid Leukemia (AML)
1 trial -
A-CAR028
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia (AML)
1 trial -
ADCLEC.syn1 CAR T cells
Takeda
Acute Myeloid Leukemia
1 trial -
ADCT-301
ADC Therapeutics SA
Acute Myeloid Leukemia
1 trial -
AG881
Agios Netherlands B.V.
Acute Myeloid Leukemia (AML)
1 trial -
APVO436
Aptevo Therapeutics
Acute Myeloid Leukemia (AML)
1 trial -
All-trans retinoic acid
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Anti-CD123 CAR NK cells
Chongqing Precision Biotech Co., Ltd
AML (Acute Myeloid Leukemia)
1 trial -
Anti-CLL1 CART cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Myeloid Leukemia
1 trial -
CAR-T cells chimeric antigen receptor T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Relapsed/Refractory Acute Myeloid Leukemia(AML)
1 trial -
CB-012
Caribou Biosciences
Acute Myeloid Leukemia, in Relapse
1 trial -
CG-806
Aptose Biosciences
Acute Myeloid Leukemia
1 trial -
CLL1 and CD38 Dual-Target CAR-T Cell Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Myeloid Leukemia
1 trial -
CLN-049
Cullinan Therapeutics
Relapsed/Refractory Acute Myeloid Leukemia (AML)
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.